Format

Send to

Choose Destination
Evid Based Complement Alternat Med. 2009 Sep;6(3):357-63. doi: 10.1093/ecam/nem126. Epub 2007 Oct 27.

Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (BiofermenticsTM).

Author information

1
Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 Japan. rshin@ciala.co.jp.

Abstract

The effects of lactic acid bacteria-fermented soybean extract (Biofermentics; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K(2)Cr(2)O(7)) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

KEYWORDS:

anti-oxidation; fermentation; hepatitis; lactobacillus; yeasts

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center